Evidence map›Paper›PMID 38808194›Full record

ArticleClinical case reports2024

Increase in antibody titer and change over time associated with severe acute respiratory syndrome coronavirus 2 infection after mRNA vaccination: Consideration of the significance of additional vaccination.

Hiroshi Kusunoki, Michiko Ohkusa, Rie Iida, Ayumi Saito, Mikio Kawahara, Kazumi Ekawa, Nozomi Kato, Masaharu Motone, Hideo Shimizu

Abstract readCase Reports
In one paragraph

Article in Clinical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hiroshi KusunokiDepartment of Internal Medicine Osaka Dental University Hirakata Japan.ORCID https://orcid.org/0000-0002-8638-7204
Michiko OhkusaDepartment of Laboratory Medicine Osaka Dental University Hospital Osaka Japan.
Rie IidaDepartment of Laboratory Medicine Osaka Dental University Hospital Osaka Japan.
Ayumi SaitoDepartment of Laboratory Medicine Osaka Dental University Hospital Osaka Japan.
Mikio KawaharaDepartment of Laboratory Medicine Osaka Dental University Hospital Osaka Japan.
Kazumi EkawaDepartment of Internal Medicine Osaka Dental University Hirakata Japan.
Nozomi KatoDepartment of Internal Medicine Osaka Dental University Hirakata Japan.
Masaharu MotoneDepartment of Internal Medicine Osaka Dental University Hirakata Japan.
Hideo ShimizuDepartment of Internal Medicine Osaka Dental University Hirakata Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Key Clinical Message: Most Japanese patients naturally infected with COVID-19 were infected after mRNA vaccination, and many maintained high antibody titers due to hybrid immunity. The significance of additional vaccination in hybrid-immunized cases is highly questionable. Abstract: Spontaneous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after mRNA vaccination causes a marked increase in antibody titer because of the combined effect of vaccine and infection ("hybrid immunity"). In this study, we discuss the significance of the mRNA vaccine booster inoculation that has been repeatedly performed in Japan. We describe the temporal trends of antibody titers in cases in which antibody titers were markedly increased by hybrid immunization. The antibody titer increased with hybrid immunization and tended to decrease with time. However, several cases maintained high antibody titers for approximately 1 year after coronavirus disease 2019 (COVID-19) diagnosis, even without booster vaccination. Most Japanese patients naturally infected with COVID-19 were infected after mRNA vaccination, and many maintained high antibody titers due to hybrid immunity. The significance of additional vaccination in hybrid-immunized cases is highly questionable regarding cost-effectiveness and risk-benefit.

Indexed as

breakthrough infectionCOVID‐19SARS‐CoV‐2SARS‐CoV‐2 antibodyvaccines

Identifiers

PMID38808194
PMCPMC11130231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.